X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
THOR-707, a precisely PEGylated, engineered version of IL-2 built on Sanofi’s Synthorin™ technology platform, is being studied in a trial of adults with advanced or metastatic solid tumors.
Lead Product(s): THOR-707,Pembrolizumab
Therapeutic Area: Oncology Product Name: THOR-707
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: ImCheck Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2021
Details:
Under the terms and conditions of the deal, Synthorx’ lead candidate THOR-707 is being tested against multiple tumour types, and will also be tested in combination with Sanofi’s own cancer drugs.
Lead Product(s): THOR-707
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $2,500.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
